TuHURA Biosciences
TuHURA Biosciences reported revenue of $0 million in fiscal 2025. Free cash flow was −$28 million. The diluted share count rose 156.8%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What TuHURA Biosciences does
TuHURA Biosciences is a small drug developer working on cancer treatments that help the immune system fight tumors. Its aim is to help patients whose cancer does not respond to, or stops responding to, immunotherapy drugs known as checkpoint inhibitors. It has no approved products and has never earned revenue from selling a drug.
Its lead drug candidate, IFx-2.0, is meant to make tumor cells look like bacteria so the body attacks them. In June 2025 it began a late-stage Phase 3 trial testing it alongside Merck's Keytruda in patients with advanced Merkel cell carcinoma, a rare skin cancer, under the FDA's faster approval route. In June 2025 it also bought Kineta, gaining TBS-2025, an antibody it plans to test in a form of acute myeloid leukemia, a blood cancer. A third, earlier program is designing drugs aimed at immune cells that shield tumors. It competes with large drug makers and other biotechnology companies.
TuHURA became a public company in October 2024 through a merger with Kintara Therapeutics. It is based in Tampa, Florida, and had 22 full-time employees at the end of 2025, most of them in research and development.
Its biggest risks, as it describes them
- Doubt about its ability to keep operating, given its continuing losses and need for more money.
- Its drug candidates may fail in clinical trials or not win approval from the FDA and other regulators.
- Its treatments use new approaches, which makes the results, timing and cost of trials hard to predict.
- Delays in enrolling patients or running its trials on the schedule it expects.
- Its reliance on outside manufacturers, research groups and trial sites to make its drugs and run its studies.
Income statement
TuHURA Biosciences lost money in fiscal 2025: a net loss of $30 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 12 | 2 | 13 | 13 | 4 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | −4.2x | −4.2x | −47.1x |
| Current ratio | 3.3x | 1.1x | 3.7x | 3.7x | 0.8x |
| Quick ratio | 3.3x | 1.1x | 3.7x | 3.7x | 0.8x |
Cash flow
Projections
Project TuHURA Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of TuHURA Biosciences reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −16.50 | −16.50 | −20.94 |
| Accruals ratio | −58.1% | −58.1% | −10.2% |
The nine F-score tests
| Test | FY24 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | — |
Compare
Put TuHURA Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| TuHURA Biosciences | FY25 | — | — | — | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Revenue growth | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | −5 | −7 | 4 | 4 | 12 | 15 | 9 | 13 | 13 | 20 |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | 8 | 11 | −8 | −9 | −38 | −23 | −15 | −22 | −22 | −30 |
| Diluted EPS (US$) | — | — | — | — | — | — | — | −1.21 | −1.21 | −0.63 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 19 | 19 | 48 |
| Cash flow | ||||||||||
| Cash from operations | −8 | −10 | −6 | −8 | −19 | −20 | −12 | −15 | −15 | −28 |
| Capital expenditure | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Free cash flow | — | — | — | — | — | — | — | −15 | −15 | −28 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 0 | 5 | 2 | 2 | 2 | 2 | 6 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 7 | 6 | 4 | 2 | 10 | 12 | 2 | 13 | 13 | 4 |
| Debt incl. finance leases | 0 | 0 | — | — | — | — | — | — | — | — |
| Total assets | 8 | 7 | 4 | 3 | 14 | 16 | 4 | 20 | 20 | 27 |
| Total liabilities | 1 | 2 | 2 | 3 | 3 | 4 | 3 | 5 | 5 | 6 |
| Shareholders' equity | 7 | 5 | 2 | 0 | 11 | 12 | 1 | 15 | 15 | 21 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 141.3% | 185.4% | −217.4% | −818.1% | −706.3% | −202.6% | −233.9% | −283.0% | −283.0% | −169.2% |
| Return on assets | 113.3% | 148.7% | −144.8% | −261.7% | −464.8% | −153.7% | −147.0% | −181.1% | −181.1% | −127.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |